Risk factors

New disclosure and control burdens follow loss of EGC status and large accelerated filer designation.

USBC shifted from medical device development to a tokenized deposit platform, Bitcoin-backed financing, and maintaining NYSE American listing compliance.

DHS CWMS 2.0 IDIQ supplied 77% of 2025 revenue and is under recompetition, with extensions only through May 24, 2026.

Exicure faces severe liquidity pressures with only $3.7 million in cash, risking ongoing operations and survival. The company relocated its headquarters to Redwood City, California, and defaulted on its sublease, facing a $0.7 million rent demand. Substantial management turnover and board changes occurred alongside changes in major shareholder ownership stakes.

Absci faces escalating financial losses, accumulating $624.8M by late 2025 while expanding its proprietary and partnered therapeutic drug pipelines.

Achieve Life Sciences faces financial distress with $15.0 million in debt and negative cash flow.

The risk section remained largely unchanged, with only minor edits to tax carryforward disclosures.

BTC Development Corp. is a blank check company with $253,000,000 in trust, seeking an initial business combination.

BioAge Labs focuses on developing its lead NLRP3 inhibitor BGE-102 for cardiometabolic and ophthalmic diseases. The company relies heavily on external third-party contractors and collaborators like Novartis. Significant ongoing capital needs and research and development expenses dominate the company's risk profile.

Biomea Fusion added new operational disclosures covering pandemics, public company employee counts, and ESG compliance. The company clarified its competitive positioning in irreversible covalent menin binders and resolved a Nasdaq audit committee deficiency by appointing Julianne Averill.

Profitability and cash burn dominate, with $103.8 million operating losses and $73.8 million operating cash use in 2025.

No new risks were added this year.